Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
The present invention concerns methods and compositions comprising an anti-IGF-1R antibody or fragment thereof for treatment of cancer or autoimmune disease. Preferably, the cancer is renal cell carcinoma, breast cancer or pancreatic cancer. The anti-IGF-1R antibody or fragment may be part of a complex, such as a DOCK-AND-LOCK™ (DNL™) (complex produced by binding interaction between anchor domain moiety of A-kinase anchoring protein and dimerization and docking domain moiety of protein kinase A regulatory subunit) complex. Preferably, the DNL™ (complex produced by binding interaction between anchor domain moiety of A-kinase anchoring protein and dimerization and docking domain moiety of protein kinase A regulatory subunit) complex also comprises a second antibody, a second antibody fragment, an affibody or a cytokine. More preferably, the cytokine is interferon-α2b. Most preferably, the second antibody, second fragment or affibody binds to IGF-1R, TROP2 or CEACAM6. The anti-IGF-1R antibody or complex may be administered alone or in combination with a therapeutic agent, such as an mTOR inhibitor.
IBC Pharmaceuticals, Inc.
A C C C C C A C C C A C C C A A A
A61K C07K C07K C07K C07K C07K A61K C07K C07K C07K A61K C07K C07K C07K A61K A61K A61K
inventional inventional additional additional additional additional inventional additional additional additional inventional inventional additional additional inventional additional inventional
David M. Chien-Hsing
Goldenberg Chang